Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.

Duell EJ, Lujan-Barroso L, Sala N, Deitz McElyea S, Overvad K, Tjonneland A, Olsen A, Weiderpass E, Busund LT, Moi L, Muller D, Vineis P, Aune D, Matullo G, Naccarati A, Panico S, Tagliabue G, Tumino R, Palli D, Kaaks R, Katzke VA, Boeing H, Bueno-de-Mesquita HBA, Peeters PH, Trichopoulou A, Lagiou P, Kotanidou A, Travis RC, Wareham N, Khaw KT, Ramon Quiros J, Rodríguez-Barranco M, Dorronsoro M, Chirlaque MD, Ardanaz E, Severi G, Boutron-Ruault MC, Rebours V, Brennan P, Gunter M, Scelo G, Cote G, Sherman S, Korc M.

Int J Cancer. 2017 Sep 1;141(5):905-915. doi: 10.1002/ijc.30790. Epub 2017 Jun 12.

2.

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.

Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M.

Cancer Lett. 2017 May 1;393:86-93. doi: 10.1016/j.canlet.2017.02.019. Epub 2017 Feb 20.

3.

A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile.

Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H, Sherman S, Korc M.

Am J Gastroenterol. 2014 Dec;109(12):1942-52. doi: 10.1038/ajg.2014.331. Epub 2014 Oct 28.

4.

Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.

Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V.

Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):321-327. doi: 10.21873/cgp.20090.

5.

Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.

Akamatsu M, Makino N, Ikeda Y, Matsuda A, Ito M, Kakizaki Y, Saito Y, Ishizawa T, Kobayashi T, Furukawa T, Ueno Y.

PLoS One. 2016 Jul 5;11(7):e0158669. doi: 10.1371/journal.pone.0158669. eCollection 2016.

6.

miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.

Alemar B, Izetti P, Gregório C, Macedo GS, Castro MA, Osvaldt AB, Matte U, Ashton-Prolla P.

Pancreas. 2016 Jan;45(1):84-92. doi: 10.1097/MPA.0000000000000383.

PMID:
26262588
7.

Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.

Sun B, Liu X, Gao Y, Li L, Dong Z.

Br J Biomed Sci. 2016 Oct;73(4):152-157.

PMID:
27922430
8.

Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.

Zhou X, Lu Z, Wang T, Huang Z, Zhu W, Miao Y.

Gene. 2018 Oct 5;673:181-193. doi: 10.1016/j.gene.2018.06.037. Epub 2018 Jun 18.

PMID:
29913239
9.

MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease.

Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S.

Cancer Prev Res (Phila). 2009 Sep;2(9):807-13. doi: 10.1158/1940-6207.CAPR-09-0094. Epub 2009 Sep 1.

10.

Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study.

Cao Z, Liu C, Xu J, You L, Wang C, Lou W, Sun B, Miao Y, Liu X, Wang X, Zhang T, Zhao Y.

Oncotarget. 2016 Jul 5;7(27):41575-41583. doi: 10.18632/oncotarget.9491.

11.

Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.

Hussein NA, Kholy ZA, Anwar MM, Ahmad MA, Ahmad SM.

J Cancer Res Clin Oncol. 2017 Jan;143(1):83-93. doi: 10.1007/s00432-016-2248-7. Epub 2016 Sep 15.

PMID:
27631726
12.

Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer.

Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM.

Med Oncol. 2013 Mar;30(1):452. doi: 10.1007/s12032-012-0452-0. Epub 2013 Jan 10.

PMID:
23307259
13.

Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.

Abue M, Yokoyama M, Shibuya R, Tamai K, Yamaguchi K, Sato I, Tanaka N, Hamada S, Shimosegawa T, Sugamura K, Satoh K.

Int J Oncol. 2015 Feb;46(2):539-47. doi: 10.3892/ijo.2014.2743. Epub 2014 Nov 10.

14.

An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker.

Goto T, Fujiya M, Konishi H, Sasajima J, Fujibayashi S, Hayashi A, Utsumi T, Sato H, Iwama T, Ijiri M, Sakatani A, Tanaka K, Nomura Y, Ueno N, Kashima S, Moriichi K, Mizukami Y, Kohgo Y, Okumura T.

BMC Cancer. 2018 Jan 31;18(1):116. doi: 10.1186/s12885-018-4006-5.

15.

Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma.

Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, Gotoh Y, Saeki K, Mori Y, Nakata K, Miyasaka Y, Onishi H, Oda Y, Goggins M, Nakamura M.

Ann Surg Oncol. 2019 Jul;26(7):2104-2111. doi: 10.1245/s10434-019-07269-z. Epub 2019 Feb 28.

PMID:
30820789
16.

Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.

Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y, Liu QH, Shi M, Ni CR, Zhu MH.

Oncol Rep. 2014 Mar;31(3):1157-64. doi: 10.3892/or.2013.2960. Epub 2013 Dec 31.

PMID:
24398877
17.

MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS.

JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664.

PMID:
24449318
18.

Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.

Yabushita S, Fukamachi K, Tanaka H, Sumida K, Deguchi Y, Sukata T, Kawamura S, Uwagawa S, Suzui M, Tsuda H.

Pancreas. 2012 Oct;41(7):1013-8. doi: 10.1097/MPA.0b013e31824ac3a5.

PMID:
22513294
19.

Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.

Fan L, Qi H, Teng J, Su B, Chen H, Wang C, Xia Q.

Tumour Biol. 2016 Jun;37(6):7777-84. doi: 10.1007/s13277-015-4608-3. Epub 2015 Dec 22.

PMID:
26695145
20.

Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.

Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.

World J Gastroenterol. 2015 Aug 21;21(31):9348-57. doi: 10.3748/wjg.v21.i31.9348.

Supplemental Content

Support Center